PDCD1 and metastatic melanoma: This finding was validated in baseline biopsies from an external cohort of metastatic melanoma patients (n = 106) treated with anti-PD-1 or sequential anti-PD-1/anti-cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4).58